Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II everolimus study in recurrent or metastatic thyroid carcinoma
NL-OMON35047Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in thyroid cancer, well-differentiated thyroid cancer (WDTC), anaplastic thyroid cancer (ATC) and 1 more (3 cohorts), sponsored by Leiden University Medical Center. Primary endpoint: Objective response rate. Started Apr 2010; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)anaplastic thyroid cancer (ATC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON35047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35047.